What is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows:

Similar documents
Tata Memorial Centre s opinion is summarized as follows:

Tata Memorial Centre s opinion is summarized as follows: We hope that the expert opinion is helpful in determining the course of your treatment.

The TMC NCG Navya opinion is summarized as follows:

Yes, the PET-CT report dated April 13 th 2016 was included in the structured summary reviewed by a medical oncologist at Tata Memorial Centre.

Tata Memorial Centre s opinion is summarized as follows: 1. Given the type 1 stricture (as mentioned in the structured summary), assessment

The TMC NCG Navya opinion is summarized as follows: or CTLA4 inhibitors (such as Iplimumab) may be considered.

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

The given bone scan and the PSA reports (as mentioned in the structured summary), suggests metastatic prostate cancer which has spread to the bones.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Conservative Surgery and Radiation Stage I and II Breast Cancer

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

My Personalized Breast Cancer Worksheet

RADIOTHERAPY IN BREAST CANCER :

Surgery for Breast Cancer

ACRIN 6666 Therapeutic Surgery Form

BreastScreen Aotearoa Annual Report 2015

3D Conformal Radiation Therapy for Mucinous Carcinoma of the Breast

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Breast Cancer. Saima Saeed MD

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues

Table of contents. Page 2 of 40

Clinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair

One Breast Cancer Annual Report

Understanding Your Pathology Report

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

Results of the ACOSOG Z0011 Trial

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Breast Cancer. For breast cancer, the mortality risk varies with the stage of the cancer.

Pathology Report Patient Companion Guide

STAGE CATEGORY DEFINITIONS

3D Conformal Radiation Therapy for Invasive Ductal Carcinoma of the Left Breast

2016 Uterine Cancer Annual Report

Radiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015

Cancer Endorsement Maintenance 2011-Maintenance Measures

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

Version STUDY PROTOCOL IRMA

Key Ouestions. to ask your medical oncology team after being diagnosed with breast cancer

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Corporate Medical Policy

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights

Early and locally advanced breast cancer: diagnosis and management

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Optical Intra-operative Assessment of Breast Tumor Margins

Pathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

Presented by: Lillian Erdahl, MD

How can surgeons help the Radiation Oncologists?

Martha Trout on 6/17/2012 at Pleasant Valley Cancer Center. Jane Plummer. Tom Plummer

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

What is the Oncotype DX test?

Case Scenario 1: Breast

SENTINEL LYMPH NODE BIOPSY FOR PATIENTS WITH EARLY-STAGE BREAST CANCER

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Geriatric Assessment to Improve Outcomes for Older Adults with Cancer

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Neoadjuvant therapy a new pathway to registration?

03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

Patient Guide to Breast Cancer Surgery and Treatment

Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:

Quiz. b. 4 High grade c. 9 Unknown

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

4/13/2010. Silverman, Buchanan Breast, 2003

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

Breast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director

Discussing Fertility Preservation with Breast Cancer Patients

CASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

NATIONAL QUALITY FORUM

Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

September 9, IORT Shows Promise in Early Use

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Seventh Edition Staging 2017 Breast

Breast Cancer in Women

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Breast Cancer. Dr. Andres Wiernik 2017

Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience

Clinical Trial Results Database Page 1

BREAST CANCER PATHOLOGY

BREAST CANCER SURGERY. Dr. John H. Donohue

SFMC Breast Cancer Site Study: 2011

Transcription:

February 3 rd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation service for Tata Memorial Centre. We converted your case reports into a structured summary to be reviewed by a radiation oncologist in the Breast Disease Management Group at Tata Memorial Centre. We asked the following question(s) on your behalf: What is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows: Adjuvant Loco Regional Radiation therapy (LRRT) with a hypofractionated schedule for the whole breast and supraclavicular fossa at a dosage of 40 Gy in 15 fractions over three weeks, along with Tumor Bed Boost (TBB) at a dosage of 12.5 Gy in 5 fractions over one week, is recommended. We hope that the expert opinion is helpful in determining the course of your treatment. Please do not hesitate to write to us or call us with any questions. Sincerely, Gitika Srivastava Navya Network Inc does not diagnose, treat, give orders, or have the ultimate authority over the care of any individuals. Page 1

CASE SUMMARY Navya ID Expert Opinion ID, Ms.. Age: 61 Years Old Past Medical History: Hypertension (High BP) Past Medical History: Diabetes - DM Type 2 Clinical Diagnosis: Operable Breast Cancer (OBC) Path TNM Stage-SubCategory: Stage IIB - T2 N1 M0 Menopausal Status: Post-Menopausal Breast Cancer Laterality: Left Lower Outer Quadrant: Yes Abdomen / Pelvis US Date: October 3rd 2014 Abdomen/ Pelvis US: Normal Prior Surgery: Timing Surgery Surgery Date Primary BCS- Lumpectomy or Wide Excision October 16th 2014 Surgery Lymph Node: Timing Surgery Surgery Date Primary Sentinel Lymph Node Dissection (SLND) October 16th 2014 Primary Axillary Lymph Node Dissection (ALND) October 16th 2014 Pathological Tumor Size (cm) Dimension 1 : 2.80 Pathological Tumor Size (cm) Dimension 2 : 1.50 Pathological Tumor Size (cm) Dimension 3 : 2.00 Number of Positive Sentinel Pathological Lymph Nodes: 1 Sentinel Pathological Lymph Nodes Resected: 2 Navya Network Inc does not diagnose, treat, give orders, or have the ultimate authority over the care of any individuals. Page 2

Number of Positive Axillary Pathological Lymph Nodes: 0 Number of Axilary Pathological Lymph Nodes Resected: 15 Malignant Breast Disease: Mucinous Carcinoma Cancer Grade: I Margins- Surgery1: Anterior <1mm Inferior <1mm Ductal Carcinoma In Situ: Yes- cribriform, comedo Lymphovascular Invasion: Positive Estrogen Receptors ER - Status: Positive (80-90%) Progesterone Receptors PR - Status: Positive (80-90%) HER 2 NEU Receptors - Status: Negative HER 2 NEU Receptors - IHC: 0 Functional Status- ECOG Score: 0 Bone Marrow (Hematologic) Function : Adequate Kidney (Renal) Function : Adequate Creatinine: 0.60 Heart (Cardiac) Function : Adequate LV Ejection Fraction: 60.00 Ki 67: 10-15% Prior Chemotherapy: Navya Network Inc does not diagnose, treat, give orders, or have the ultimate authority over the care of any individuals. Page 3

Timing Chemotherapy SubCategory Treatment Start Date Treatment End Date Adjuvant AC- A(60)C(600)q3w*4 November 12th 2014 January 12th 2015 Note: 5th cycle of chemotherapy scheduled for Feb 5th 2014 Navya Network Inc does not diagnose, treat, give orders, or have the ultimate authority over the care of any individuals. Page 4

Navya Network is a Cambridge, MA based company with offices in Bangalore, India. Navya Network is founded by graduates of Harvard University, MIT Sloan School of Management, and the Stanford School of Medicine. Navya s innovative and scalable decision making system is a technology powered solution for complex medical questions. Navya s software solutions are efficient engines to gather and synthesize individual goals of care, evidence specific to an individual medical case, and expert opinion, for evaluating treatment alternatives. Navya s goal is to assist in bringing clarity to the complexity of evaluating treatment alternatives. Navya s system collects the best available information and expertise from several worldwide sources relevant to a specific previously diagnosed medical case and assesses treatment decisions. For more information, please visit www.navyanetwork.com If you have any questions, please call +91 9845423460 or email gitika@navyatech.in Navya Network, Inc does not diagnose, prescribe medication, treat, or give orders, nor does Navya have the ultimate authority over the care of any individuals. Navya does not provide medical advice nor does its products, services, systems, projects, or programs constitute the practice of medicine, nursing, or any other health care profession. Any information provided by Navya as a result of use of Navya s products, services, systems, projects, or programs is being provided solely for educational and informational benefit and should not be considered diagnosis, treatment or a substitute for professional medical advice. Use of Navya s products, services, systems, projects, or programs does not establish a doctor-patient relationship. Navya encourages that individuals or patients using Navya s products, services, systems, projects, or programs share any reports or other information generated by the use of Navya s products, services, systems, projects, or programs with their treating health care provider. Use of Navya s products, services, systems, projects, or programs is voluntary and any information communicated as a result of the use of Navya s products, services, systems, projects, or programs is not intended to be, nor implied to be, and cannot and should not be used as a substitute for professional medical advice, diagnosis or treatment. Navya s products, services, systems, projects, or programs are limited to the provision of consultative services with respect to known or previously-identified condition and neither Navya, nor its employees, consultants or agents with whom it contracts will diagnose, treat, give orders, prescribe medications or have any authority over the care of any individuals. Navya s products, services, systems, projects, or programs will not involve any direct face-to-face encounters or physical examinations. Accordingly, individuals using Navya s products, services, systems, projects, or programs are encouraged to share and discuss any information provided as a result of use of Navya s products, services, systems, projects, or programs with their treating physician. The individuals or patients using Navya s products, services, systems, projects, or programs will be the ultimate decision maker over their own care. Navya Network Inc does not diagnose, treat, give orders, or have the ultimate authority over the care of any individuals. Page 5

INDIVIDUALS OR PATIENTS USING NAVYA S PRODUCTS, SERVICES, SYSTEMS, PROJECTS, OR PROGRAMS SHOULD NEVER DELAY OR AVOID SEEKING MEDICAL ADVICE OR ATTENTION FROM THEIR REGULAR HEALTH CARE PROVIDER OR TREATING PHYSICIAN OR DOCTOR BECAUSE OF SOMETHING THEY HAVE LEARNED THROUGH THEIR USE OF NAVYA S PRODUCTS, SERVICES, SYSTEMS, PROJECTS, OR PROGRAMS. SHOULD ANY UNEXPECTED MEDICAL EVENT OCCUR WHILE AN INDIVIDUAL OR A PATIENT IS PARTICIPATING IN THE USE OF NAVYA S PRODUCTS, SERVICES, SYSTEMS, PROJECTS, OR PROGRAMS, THE INDIVIDUAL OR THE PATIENT SHOULD IMMEDIATELY CALL THEIR HEALTH CARE PROVIDER OR TREATING PHYSICIAN OR DOCTOR OR LOCAL EMERGENCY ASSISTANCE NUMBER OR IMMEDIATELY VISIT THEIR LOCAL EMERGENCY ROOM. Navya Network Inc does not diagnose, treat, give orders, or have the ultimate authority over the care of any individuals. Page 6